Acquisition - March 6, 2026
Sectra acquires Oxipit
Sectra has entered into an agreement to acquire Oxipit, a Lithuanian company specializing in AI-based solutions for radiology.
MedTech Business - March 2, 2026
SciBase receives FDA approval for extended labelling in the US
The company has received approval by FDA for its supplement to extend the labelling to include other healthcare professionals and not only dermatologists to perform the Nevisense procedure.
MedTech Business - February 23, 2026
FDA clears FluoGuide’s IND for FG001 in High-Grade Glioma
The US Food and Drug Administration (FDA) has informed the company that it can proceed with the proposed clinical investigation for FG001.
MedTech Business - February 16, 2026
FDA grants De Novo Classification request from Amferia
Amferia's antibacterial wound dressing has been granted approval by the US Food and Drug Administration (FDA) through the De Novo Classification Request track, allowing Amferia to enter the US market with a unique Class 2 medical device antibacterial dressing for advanced wound care.
Acquisition - February 12, 2026
Devyser acquires Cybergene
Devyser Diagnostics has entered into an agreement relating to the acquisition of 100 percent of the shares in Cybergene AB, a Swedish company within the Level Bio group.
MedTech Business - February 3, 2026
ADDvise has applied for delisting from Nasdaq First North
On 10 December 2025, Amplex announced a public offer to the holders of shares and warrants of ADDvise Group. On 27 January 2026, Amplex announced that the offer had been accepted to such extent that Amplex will become the owner of 94.31 per cent of all shares in ADDvise upon settlement of the offer.
